Heparin: From animal organ extract to designer drug

Thrombosis Research

Volumn 122, Issue 6, 2008, Pages 753-762

  Middeldorp, S ^a  

^a Department of Endocrinology and General Internal Medicine   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; ARDEPARIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTASACCHARIDE; PLACEBO; REVIPARIN; THROMBIN; TINZAPARIN; WARFARIN;

ADD ON THERAPY; ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; DESIGNER DRUGS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDIC PROCEDURES; PULMONARY EMBOLISM; THROMBOSIS; VENOUS THROMBOSIS;

EID: 52249108492     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.07.004     Document Type: Review

References (64)

1. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 188S-203S
2. Owen C.A. Current methods of therapy: heparin. In: Nichols W.L., and Bowie E.J.W. (Eds). A history of blood coagulation (2001), Mayo Foundation for Medical Education and Research, Rochester 245-256
3. Rosenberg R.D., and Damus P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248 18 (Sep 25 1973) 6490-6505
4. Lam L.H., Silbert J.E., and Rosenberg R.D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69 2 (Mar 22 1976) 570-577
5. Rosenberg R.D. Redesigning heparin. N Engl J Med 344 9 (Mar 1 2001) 673-675
6. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 10 (Sep 4 1997) 688-698
7. Danielsson A., Raub E., Lindahl U., and Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 261 33 (Nov 25 1986) 15467-15473
8. Jordan R.E., Oosta G.M., Gardner W.T., and Rosenberg R.D. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 255 21 (Nov 10 1980) 10081-10090
9. Weitz J.I. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 96 3 (Sep 2006) 274-284
10. Savi P., Chong B.H., Greinacher A., Gruel Y., Kelton J.G., Warkentin T.E., et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105 1 (Jan 1 2005) 139-144
11. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 338S-400S
12. Collins R., Scrimgeour A., Yusuf S., and Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 318 18 (May 5 1988) 1162-1173
13. Mismetti P., Laporte S., Darmon J.Y., Buchmuller A., and Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88 7 (Jul 2001) 913-930
14. Koch A., Bouges S., Ziegler S., Dinkel H., Daures J.P., and Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 84 6 (Jun 1997) 750-759
15. Agnelli G., Bergqvist D., Cohen A.T., Gallus A.S., and Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 10 (Oct 2005) 1212-1220
16. Turpie A.G., Bauer K.A., Eriksson B.I., and Lassen M.R. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359 9319 (May 18 2002) 1721-1726
17. Lassen M.R., Bauer K.A., Eriksson B.I., and Turpie A.G. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359 9319 (May 18 2002) 1715-1720
18. Bauer K.A., Eriksson B.I., Lassen M.R., and Turpie A.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345 18 (Nov 1 2001) 1305-1310
19. Eriksson B.I., Bauer K.A., Lassen M.R., and Turpie A.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345 18 (Nov 1 2001) 1298-1304
20. Turpie A.G., Eriksson B.I., Lassen M.R., and Bauer K.A. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 11 4 (2002) 182-188
21. Geerts W., Heit J.A., Clagett G.P., Pineo G.F., Colwell C.W., Anderson Jr. F.A., et al. Prevention of venous thromboembolism. Chest 119 (2001) 132S-175S
22. Turpie A.G., Bauer K.A., Eriksson B.I., and Lassen M.R. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 126 2 (Aug 2004) 501-508
23. O'Donnell M., Linkins L.A., Kearon C., Julian J., and Hirsh J. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med 163 11 (Jun 9 2003) 1362-1366
24. Thaler H.W., Roller R.E., Greiner N., Sim E., and Korninger C. Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. J Trauma 51 3 (Sep 2001) 518-521
25. Eriksson B.I., and Lassen M.R. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163 11 (Jun 9 2003) 1337-1342
26. Schuurman B., den H.M., and Nijs A.M. Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense?. Neth J Med 56 5 (May 2000) 171-176
27. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341 11 (Sep 9 1999) 793-800
28. Leizorovicz A., Cohen A.T., Turpie A.G.G., Olsson C.G., Vaitkus P.T., Goldhaber S.Z., et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 7 (Aug 17 2004) 874-879
29. Bergmann J.F., and Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 76 4 (Oct 1996) 529-534
30. Harenberg J., Roebruck P., and Heene D.L. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 26 3 (May 1996) 127-139
31. Kleber F.X., Witt C., Vogel G., Koppenhagen K., Schomaker U., and Flosbach C.W. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145 4 (Apr 2003) 614-621
32. Cohen A.T., Davidson B.L., Gallus A.S., Lassen M.R., Prins M.H., Tomkowski W., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332 7537 (Feb 11 2006) 325-329
33. Girolami B., Prandoni P., Stefani P.M., Tanduo C., Sabbion P., Eichler P., et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101 8 (Apr 15 2003) 2955-2959
34. Prandoni P., et al., BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106 9 (Nov 1 2005) 3049-3054
35. Murray G., and Best C. Heparin and thrombosis: the present situation. JAMA 110 (1938) 118-122
36. Bauer G. Thrombosis early diagnosis and abortive treatment with heparin. Lancet 247 6396 (Mar 30 1946) 447-454
37. Barritt D.W., and Jordan S.C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 275 7138 (Jun 18 1960) 1309-1312
38. Brandjes D.P., Heijboer H., Buller H.R., de Rijk M., Jagt H., and ten Cate J.W. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 327 21 (1992) 1485-1489
39. Hull R.D., Raskob G.E., Rosenbloom D., Panju A.A., Brill-Edwards P., Ginsberg J.S., et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322 18 (May 3 1990) 1260-1264
40. van Dongen C.J., van den Belt A.G., Prins M.H., and Lensing A.W. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 4 (2004) CD001100
41. Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., van, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared wtih subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group [see comments]. N Engl J Med 334 11 (1996) 682-687
42. Levine M., Gent M., Hirsh J., LeClerc J., Anderson D., Weitz J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 11 (Mar 14 1996) 677-681
43. Buller H.R., Sohne M., and Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost 3 8 (Aug 2005) 1554-1560
44. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 11 (Jun 1 2004) 867-873
45. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 18 (Oct 30 2003) 1695-1702
46. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Sep 2004) 401S-428S
47. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 15 (Aug 12 2002) 1729-1735
48. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 2 (Jul 10 2003) 146-153
49. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 10 (2005 Apr 1) 2123-2129
50. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2 1 (Jan 2004) 47-53
51. Menon V., Harrington R.A., Hochman J.S., Cannon C.P., Goodman S.D., Wilcox R.G., et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 549S-575S
52. Antman E.M., Morrow D.A., McCabe C.H., Murphy S.A., Ruda M., Sadowski Z., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 14 (Apr 6 2006) 1477-1488
53. Harrington R.A., Becker R.C., Ezekowitz M., Meade T.W., O'Connor C.M., Vorchheimer D.A., et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 513S-548S
54. The OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
55. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 14 (Apr 6 2006) 1464-1476
56. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., Levine M., Prins M.H., and Buller H.R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82 2 (Aug 1999) 947-952
57. Smorenburg S.M., Hettiarachchi R.J., Vink R., and Buller H.R. The effects of unfractionated heparin on survival in patients with malignancy-a systematic review. Thromb Haemost 82 6 (Dec 1999) 1600-1604
58. Lebeau B., Chastang C., Brechot J.M., Capron F., Dautzenberg B., Delaisements C., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 74 1 (Jul 1 1994) 38-45
59. Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 8 (Aug 2004) 1266-1271
60. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 10 (Apr 1 2005) 2130-2135
61. Sideras K., Schaefer P.L., Okuno S.H., Sloan J.A., Kutteh L., Fitch T.R., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81 6 (Jun 2006) 758-767
62. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 10 (May 15 2004) 1944-1948
63. Akl E.A., van Doormaal F.F., Barba M., Kamath G., Kim S.Y., and Kuipers S. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database of Syst. Rev. 3 (2007) [Art. No.: CD006652], doi:10.1002/14651858.CD006652
64. van Doormaal F.F., Buller H.R., Middeldorp S. The role of new antithrombotics in cancer. Critical Reviews in Oncology/Hematology. In press.